XML 42 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1Close
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
12 Months Ended
Feb. 03, 2024
Jan. 28, 2023
Jan. 29, 2022
Operating activities      
Net earnings $ 4,138 $ 2,780 $ 6,946
Adjustments to reconcile net earnings to cash provided by operations:      
Depreciation and amortization 2,801 2,700 2,642
Share-based compensation expense 251 220 228
Deferred income taxes 298 582 522
Gain on Dermstore sale 0 0 (335)
Noncash losses / (gains) and other, net 94 172 67
Changes in operating accounts:      
Inventory 1,613 403 (3,249)
Other assets (85) 22 (78)
Accounts payable (1,216) (2,237) 2,628
Accrued and other liabilities 727 (624) (746)
Cash provided by operating activities 8,621 4,018 8,625 Close
Investing activities      
Expenditures for property and equipment (4,806) (5,528) (3,544)
Proceeds from disposal of property and equipment 24 8 27
Proceeds from Dermstore sale 0 0 356
Other investments 22 16 7
Cash required for investing activities (4,760) (5,504) (3,154)
Financing activities      
Additions to long-term debt 0 2,625 1,972
Reductions of long-term debt (147) (163) (1,147)
Dividends paid (2,011) (1,836) (1,548)
Repurchase of stock 0 (2,646) (7,188)
Shares withheld for taxes on share-based compensation (127) (180) (168)
Stock option exercises 0 4 8
Cash required for financing activities (2,285) (2,196) (8,071) Close
Net increase / (decrease) in cash and cash equivalents 1,576 (3,682) (2,600) Close
Cash and cash equivalents at beginning of period 2,229 5,911 8,511
Cash and cash equivalents at end of period 3,805 2,229 5,911
Supplemental information      
Interest paid, net of capitalized interest 605 449 414
Income taxes paid 374 213 2,063
Leased assets obtained in exchange for new finance lease liabilities 104 224 288
Leased assets obtained in exchange for new operating lease liabilities $ 1,027 $ 329 $ 580